Pritumumab

Pritumumab is a human monoclonal antibody against vimentin developed by Nascent Biotech. It is in clinical trials for the treatment of glioma. The FDA granted orphan drug designation in 2015. '-mexi-' (melanoma): Ecromeximab§ Pritumumab is a human monoclonal antibody against vimentin developed by Nascent Biotech. It is in clinical trials for the treatment of glioma. The FDA granted orphan drug designation in 2015.